VacZine Analytics  

ExpertREACT is a monthly newsletter service to our subscribers.

The aim of ExpectREACT is to respond to events within the vaccines sector and communicate to our clients their potential impact and significance. It will also provide summary discussion pieces from our ongoing work with global opinion leaders.

PREMIUM These articles are supplied on a pay per view basis.
Usable print versions of other articles can also be obtained. Click here>>

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up with e-mail address to ExpertREACT
Current market dynamics:

April 2017:
2016 FY results - the impact of real use and true product innovation.

February 2017:
Vaccines in the Trump era.

December 2016:
2016 - year of the flavivirus vaccine.

November 2016:
2017 places higher pressure on hospitals to avoid HAIs.

September 2016:
A Zika vaccine - the case strengthens.

May 2016:
The global influenza vaccine market - where next?

March 2016:
2015 FY - Pfizer grows vaccine industry.

February 2016:
A Zika vaccine - late to the party we must attend

December 2015:
2015 - The year of meningitis vaccines

August 2015:
2015 Q2 - round up of results and R&D

May 2015:
Human metapneumovirus - why the poor cousin of RSV?

March 2015:
2014 FY Results - vaccine industry, still bumping along.

December 2014:
Top ten vaccine industry events - 2015.

November 2014:
Influenza vaccines - more options but don't lose sight of longer term.

October 2014:
No room for blame after our surprise from Ebola.

September 2014:
54th ICAAC, Washington DC conference - selective innovation won't do.

August 2014:
Pfizer vaccines boosts presence with low risk Baxter acquisitions.

June 2014:
Caribbean Chikungunya outbreak should move vaccine back onto the agenda.

April 2014:
Novartis to the vaccines industry - can we have our money back please?

March 2014:
BexseroŽ: good for UK children, Novartis Vaccines and a flat industry.

February 2014:
2013 FY results - QIVs a highlight in a flat industry

December 2013:
Clostridium difficile vaccines: multipronged US-biased strategy to reduce economic burden.

November 2013:
Meningococcal group B vaccine, BexseroŽ: too late for the science? Stick to the wider economics

October 2013:
Who will benefit from the predicted boom in inactivated polio virus vaccines?

September 2013:
Middle East respiratory syndrome coronavirus (MERS-CoV) - worry, but dont panic.

August 2013:
Q2 2013 - Roundup of results and R&D

June 2013:
M&A in the vaccine sector.

March 2013:
PCSK9 mAbs or even vaccines - the new statins?

February 2013:
2012 FY results - a flat industry poised for growth.

January 2013:
Protein Sciences FluBlok - finally here but much still to be done.

December 2012:
2012 - another year for the vaccine industry.

October 2012:
Latest review of the vaccine R&D pipeline - Autumn 2012.

August 2012:
The vaccines industry: Q2 2012 round-up of results and R&D.

June 2012:
Quadrivalent influenza vaccines: full switch or niche position?

April 2012:
Is it still worth developing a Staph vaccine?

February 2012:
2011 FY Results - vaccine industry waiting for next burst of growth.

January 2012:
A(H5N1), Avian influenza - still with us, ready to pounce?

November 2011:
Vaccine major players - Q3 round-up of results and R&D.

September 2011:
XVIII Lancefield International Symposium, Palermo, Sicily......vaccine update.

June 2011:
Melanoma vaccines - have Roche and BMS moved the goal posts?

May 2011:
New vaccines for dengue. Paying adults please.

March 2011:
2010 FY Results. Its more than H1N1.......

January 2011:
The current industry landscape for therapeutic vaccines.

December 2010:
The vaccine industry in 2010 - highlights and lowlights.

November 2010:
How much is the current R&D vaccine pipeline worth? PREMIUM
Vaccine major players - Q3 round up of results and R&D

September 2010:
Discussing vaccines at the 50th ICAAC Boston.

August 2010:
Vaccine major players - Q2 round up of results and R&D
Considerations when commercial modelling a universal influenza vaccine. PREMIUM

June 2010:
A credible GBS vaccine - finally back on the agenda

May 2010:
Vaccine major players - Q1 round up of results and R&D

April 2010:
Healthcare acquired infections and vaccines - the profile determines everything. PREMIUM

March 2010:
Vaccines and Japanese Encephalitis - too early to call for Ixiaro?

February 2010:
The vaccine industry in 2009 - well past the $20 billion barrier.

January 2010:
H1N1 - boost to Novartis Vaccines, the industry but for how long?

December 2009:
2009 and vaccines - lots of activity, and surprises.

November 2009:
New meningitis B vaccines - does the best science matter? PREMIUM
Rethinking new meningitis ACWY vaccines.
How to monitor fast moving vaccine R&D.

October 2009:
New vaccine adjuvants - MPL paves the way.
H1N1 vaccines - the pros and cons of new technologies.

September 2009:
Vaccinating teenagers - growth platform.

August 2009:
Enterovirus-71: a long-term bet for the SE Asia region? PREMIUM
Latest vaccine R&D pipeline - flu sets agenda.

June 2009:
Chikungunya virus - should we think now about a vaccine?
Prevnar and PCV-13 versus Synflorix - waging war at 27th ESPID with antibody levels. PREMIUM

May 2009:
Major vaccine players - the race to Japan.
Modelling H1N1 vaccine demand - another multibillion dollar issue.

April 2009:
Swine flu (H1N1) reminds us our flu vaccine technologies need updating.
GSKs Synflorix and Non-typeable H.influenzae - the secret to beating Wyeth? PREMIUM

March 2009:
Pandemic flu - building the case to prime now.

February 2009:
The vaccine industry - still growing, but more slowly.

January 2009:
GSK and Synflorix: closer to a different marketplace? PREMIUM
Wyeth and vaccines: first acquiring then acquired.
US Pandemic Planning Update VI - strong vaccine progress to date.

December 2008:
The vaccine movers and shakers of 2008. Looking towards 2009.
GSK malaria vaccine - a positive step for novel adjuvant systems?

November 2008:
Clostridium difficile - the bad news and possibly good news.

October 2008:
The vaccine R&D pipeline - is influenza being overdone?
GSK Bio and AFFiRiS - are therapeutic vaccines back in fashion?
48th Annual ICAAC/IDSA, Washington, DC - vaccines update.

September 2008:
Norovirus vaccines: time for re-examination?

August 2008:
New US flu vaccine recommendations: continued focus on children.

July 2008
Respiratory syncytial virus - not just for kids..
Group A Streptococcus vaccines - considering the issues.
Sanofi to acquire Acambis - the logical next step.

June 2008:
Novartis Vaccines: diverse early stage pipeline will force rivals to act.

May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007

© 2013 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains